Funding for this research was provided by:
Merck Sharp & Dohme, Spain
Text and Data Mining valid from 2018-11-15
First Online: 15 November 2018
Compliance with Ethical Standards
: This project was funded by Merck Sharp and Dohme, Spain.
: Domingo Orozco-Beltrán has provided consultancy services to MSD and Novartis and has lectured for Novartis, Mundipharma, Novo, Sanofi Aventis and Lilly. María J. Galindo has provided consultancy services to Viiv, Abbie, MSD, Gilead and Janssen; her institution has received grants from MSD, Janssen and Gilead and payments for travel to meetings from MSD and for lectures or educational presentations from MSD, Janssen, Gilead and Viiv. Ignacio Marín-Jiménez has received research funding (to his institution) and payment for acting as a consultant, advisory member or speaker from AbbVie, Chiesi, Faes Farma, Falk-Pharma, Ferring, Gebro Pharma, Hospira, Janssen, MSD, Otsuka Pharmaceutical, Pfizer, Shire, Takeda, Tillots and UCB Pharma. Francesc Casellas has received research funding (to his institution) from AbbVie, MSD, Shire, Ferring and Zambon and speaker fees from AbbVie, MSD, Shire, Ferring and Zambon. María J. Fuster-RuizdeApodaca has received research funding (to her institution) from ViiV Healthcare, MSD, Janssen and Gilead and payments for consultancy services (to her institution) from Gilead, ViiV Healthcare and Janssen and for lectures (to her institution) from Gilead and ViiV Healthcare. María L. García-Vivar has provided consultancy services to MSD, BMS and Janssen and expert testimony for AbbVie and Pfizer and has received grants (to her institution) from Roche, MSD and UCB and payments for lectures from Novartis, GSK, Celgene, Lilly, Janssen, AbbVie and Pfizer. Mercedes Guilabert has received consultancy and travel/meeting expenses from MSD. Nuria Sánchez-Vega, Gonzalo Fernández and Luis Cea-Calvo are full-time employees of MSD Spain. Javier de Toro and Antonio Hormigo-Pozo have no conflicts of interest that are directly related to the content of this article.